{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:08Z","timestamp":1792081508517,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Enteropathy is a non-infectious complication in Common Variable Immune Deficiency (CVID) associated with increased morbidity and mortality. We characterized this group of CVID enteropathy (CVID-E) patients and investigated the effectiveness of immunosuppressive treatments on its clinical course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We identified patients with CVID-E in two academic teaching hospitals and obtained informed consents. Using electronic patient health care records, we retrospectively collected clinical information in the national Primary immunodeficiency disorder database until 01-2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 39 patients with CVID-E. Bronchiectasis (69.2%) and lymphoproliferation (46.1%) were the most frequent co-occurring symptoms. The most common endoscopy findings concerned inflammation (72.2%) and erythema (69.4%); The most prevalent histopathologic findings were IBD-like inflammation (55.6%), indiscriminate chronic inflammation (47.2%) and indiscriminate active inflammation (38.9%). We assessed 88 events of treatment response in the 25 treated patients. Overall treatment response was poor, however there were 31 events of remission observed, ranging from partial to sustained remission. Of these 26 were the result of tumor necrosis factor inhibitors (TNFi) or thiopurines, either as monotherapy or in combination with other immunosuppressive treatment. 10 patients achieved complete remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, we describe a cohort of CVID-E patients including related comorbidity, clinical course and response to therapy. CVID-E patients frequently develop other, sometimes severe comorbidities. Our study confirms the alleged heterogeneity regarding endoscopic and histopathological findings, and in one third of patients even multiple distinct abnormalities co-occurred in the same biopsy. We found azathioprine and\/or TNFi to be the most effective current treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10875-025-01920-z","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:49:09Z","timestamp":1759218549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CVID Enteropathy Is Difficult To Treat and Shows a Heterogeneous Histopathology"],"prefix":"10.1007","volume":"45","author":[{"given":"Noah M.","family":"Juliana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Severs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris M.","family":"van Montfrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline M.","family":"Ellerbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miangela M.","family":"Lacle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A.S.H.","family":"Dalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Abelmoumen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen. L.","family":"Leavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"4","key":"1920_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s10875-014-0028-1","volume":"34","author":"KE Sullivan","year":"2014","unstructured":"Sullivan KE, Puck JM, Notarangelo LD, Ramsay Fuleihan, Caulder T, Wang CW, et al. USIDNET: a strategy to build a community of clinical immunologists. J Clin Immunol. 2014;34(4):428\u201335.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1920_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/cei.12105","volume":"173","author":"B Gathmann","year":"2013","unstructured":"Gathmann B, Goldacker S, Klima M, Belohradsky BH, Notheis G, Ehl S, et al. The German National registry for primary immunodeficiencies (PID). Clin Experimental Immunol. 2013;173(2):372\u201380.","journal-title":"Clin Experimental Immunol"},{"key":"1920_CR3","unstructured":"Pescador Ruschel MA, Vaqar S. Common Variable Immunodeficiency (CVID) [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020. Available from https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549787\/. Accessed Jan 2025"},{"key":"1920_CR4","doi-asserted-by":"publisher","unstructured":"Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions.\u00a0Br J Haematol. 2009;145(6):709\u201327. Available from: https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07669.x; https:\/\/onlinelibrary.wiley.com\/doi\/abs\/. Accessed Jun 2009","DOI":"10.1111\/j.1365-2141.2009.07669.x"},{"issue":"1","key":"1920_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaci.2013.12.1077","volume":"134","author":"B Gathmann","year":"2014","unstructured":"Gathmann B, Mahlaoui N, G\u00e9rard L, Oksenhendler E, Warnatz K, Schulze I, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116\u2013e12611.","journal-title":"J Allergy Clin Immunol"},{"key":"1920_CR6","unstructured":"Fischer A, Provot J, Jais JP, Alcais A, Mahlaoui N, Adoue D et al. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies.\u00a0J Allergy Clin Immunol. 2017;140(5):1388\u20131393.e8. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0091674917302269. Accessed 10 Feb 2017"},{"key":"1920_CR7","doi-asserted-by":"crossref","unstructured":"Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood [Internet]. 2008 Jul 15 [cited 2021 Jan 20];112(2):277\u201386. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18319398\/. Accessed 4 Mar 2008","DOI":"10.1182\/blood-2007-11-124545"},{"issue":"5","key":"1920_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s10875-010-9424-3","volume":"30","author":"M Ga\u00ebl Mouillot","year":"2010","unstructured":"Ga\u00ebl Mouillot M, Carmagnat, G\u00e9rard L, Garnier JL, Fieschi C, Vince N, et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol. 2010;30(5):746\u201355.","journal-title":"J Clin Immunol"},{"key":"1920_CR9","doi-asserted-by":"crossref","unstructured":"Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2011;119(7):1650\u20137. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3286343\/. Accessed 16 Feb 2012","DOI":"10.1182\/blood-2011-09-377945"},{"issue":"10","key":"1920_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/ajg.2016.329","volume":"111","author":"SF J\u00f8rgensen","year":"2016","unstructured":"J\u00f8rgensen SF, Reims HM, Frydenlund DS, Holm K, Paulsen V, Michelsen AE, et al. A cross-sectional study of the prevalence of gastrointestinal symptoms and pathology in patients with common variable immunodeficiency. Am J Gastroenterol. 2016;111(10):1467\u201375.","journal-title":"Am J Gastroenterol"},{"key":"1920_CR11","doi-asserted-by":"publisher","unstructured":"Ho H, Cunningham-Rundles C. Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol. 2020;7(11):149.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2020.00149","DOI":"10.3389\/fimmu.2020.00149"},{"key":"1920_CR12","doi-asserted-by":"crossref","unstructured":"Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal Tract Pathology in Patients With Common Variable Immunodeficiency (CVID): A Clinicopathologic Study and Review.\u00a0Am J Surg Pathol 2007;31(12):1800\u201312. Available from: https:\/\/journals.lww.com\/ajsp\/Abstract\/2007\/12000\/Gastrointestinal_Tract_Pathology_in_Patients_With.3.aspx. Accessed Dec 2007","DOI":"10.1097\/PAS.0b013e3180cab60c"},{"key":"1920_CR13","doi-asserted-by":"crossref","unstructured":"Washington K, Stenzel TT, Buckley RH, Gottfried MR. Gastrointestinal Pathology in Patients with Common Variable Immunodeficiency and X-Linked Agammaglobulinemia.\u00a0Am J Surg Pathol. 1996;20(10):1240. Available from: https:\/\/journals.lww.com\/ajsp\/fulltext\/1996\/10000\/gastrointestinal_pathology_in_patients_with_common.10.aspx. Accessed Oct 1996","DOI":"10.1097\/00000478-199610000-00010"},{"key":"1920_CR14","doi-asserted-by":"crossref","unstructured":"Oksenhendler E, G\u00e9rard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R et al. Infections in 252 Patients with Common Variable Immunodeficiency.\u00a0Clin Infect Dis. 2008;46(10):1547\u201354. Available from: https:\/\/academic.oup.com\/cid\/article\/46\/10\/1547\/293493. Accessed 15 May 2008","DOI":"10.1086\/587669"},{"issue":"20","key":"1920_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World medical association declaration of Helsinki. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"key":"1920_CR16","doi-asserted-by":"publisher","unstructured":"Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42:1473\u20131507.\u00a0https:\/\/doi.org\/10.1007\/s10875-022-01289-3","DOI":"10.1007\/s10875-022-01289-3"},{"key":"1920_CR17","unstructured":"Al-Hussieni KJMR, Rasouli SE, Azizi G, Mosavian M, Matani R, Porrostami K et al. Gastrointestinal Manifestations in Patients with Common Variable Immunodeficiency.\u00a0Immunol Genet J. 2019;2(4):185\u201395. Available from: https:\/\/igj.tums.ac.ir\/index.php\/igj\/article\/view\/37. Accessed 22 Dec 2019"},{"key":"1920_CR18","doi-asserted-by":"crossref","unstructured":"Khan R, Habbal M, Scaffidi MA, Bukhari AA, Rumman A, Al Ghamdi S et al. Gastrointestinal Disease in Patients with Common Variable Immunodeficiency: A Retrospective Observational Study.\u00a0J Can Assoc Gastroenterol. 2020;3(4):162\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32671325\/. Accessed 25 Feb 2019","DOI":"10.1093\/jcag\/gwz004"},{"key":"1920_CR19","doi-asserted-by":"crossref","unstructured":"Sanchez DA, Rotella K, Toribio C, Hernandez M, Cunningham-Rundles C. Characterization of infectious and non-infectious gastrointestinal disease in common variable immunodeficiency: analysis of 114 patient cohort.\u00a0Front Immunol\u00a02023;14(14):1209570. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37711607\/. Accessed 30 Aug 2023","DOI":"10.3389\/fimmu.2023.1209570"},{"key":"1920_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01604-6","author":"LE Franzblau","year":"2023","unstructured":"Franzblau LE, Fuleihan RL, Cunningham-Rundles C, Wysocki CA. CVID-associated intestinal disorders in the USIDNET registry: an analysis of disease manifestations, functional status, comorbidities, and treatment. J Clin Immunol. 2024 44:32. https:\/\/doi.org\/10.1007\/s10875-023-01604-6","journal-title":"J Clin Immunol"},{"key":"1920_CR21","doi-asserted-by":"publisher","unstructured":"Gibiino G et al. Jan. Coeliac disease under a microscope: histological diagnostic features and confounding factors.\u00a0Comput Biol Med. 2020;104:335\u2013338.\u00a0https:\/\/doi.org\/10.1016\/j.compbiomed.2018.10.020https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0010482518303196?via%3Dihub. Accessed 19 Oct 2018","DOI":"10.1016\/j.compbiomed.2018.10.020"},{"issue":"no. 4","key":"1920_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5946\/ce.2016.090","volume":"49","author":"JM Lee","year":"2016","unstructured":"Lee JM, Lee K-M. Endoscopic diagnosis and differentiation of inflammatory bowel disease. Clin Endosc. 2016;49(4):370\u20135. https:\/\/doi.org\/10.5946\/ce.2016.090.","journal-title":"Clin Endosc"},{"key":"1920_CR23","doi-asserted-by":"publisher","unstructured":"Magro F et al. Nov european consensus on the histopathology of inflammatory bowel disease.\u00a0J Crohns Colitis. 2013;7(10):827\u2013851. https:\/\/doi.org\/10.1016\/j.crohns.2013.06.00; https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1873994613002055. Accessed 17 Jul 2013","DOI":"10.1016\/j.crohns.2013.06.00"},{"key":"1920_CR24","doi-asserted-by":"publisher","unstructured":"van Schewick C et al. Oct bowel histology of CVID patients reveals distinct patterns of mucosal inflammation. J Clin Immunol. 2024;42(1):46\u201359. https:\/\/doi.org\/10.1007\/s10875-021-01104-5. Accessed 3 June 2024.","DOI":"10.1007\/s10875-021-01104-5"},{"key":"1920_CR25","doi-asserted-by":"publisher","unstructured":"Strohmeier V et al. Oct interferon-driven immune dysregulation in common variable immunodeficiency\u2013associated villous atrophy and norovirus infection.\u00a0J Clin Immunol. 2022;43(2):371\u2013390. https:\/\/doi.org\/10.1007\/s10875-022-01379-2. Accessed 3 May 2024.","DOI":"10.1007\/s10875-022-01379-2"},{"key":"1920_CR26","doi-asserted-by":"publisher","unstructured":"Gentile NM et al. July autoimmune enteropathy: a review and update of clinical management.\u00a0Curr Gastroenterol Rep. 2012;14(5):380\u2013385. https:\/\/doi.org\/10.1007\/s11894-012-0276-2. Accessed 11 Nov 2020.","DOI":"10.1007\/s11894-012-0276-2"},{"issue":"5","key":"1920_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.cgh.2022.07.030","volume":"21","author":"M Fabienne Charbit-Henrion, Haas","year":"2023","unstructured":"Fabienne Charbit-Henrion, Haas M, Stanislas Chaussade C, Cellier, Cerf\u2010Bensussan N, Malamut G, et al. Genetic diagnosis guides treatment of autoimmune enteropathy. Clin Gastroenterol Hepatol. 2023;21(5):1368\u2013e13712.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1920_CR28","doi-asserted-by":"crossref","unstructured":"Arieira C, Dias de Castro F, Moreira M, Cotter J. Common variable immunodeficiency-associated inflammatory enteropathy: the new era of biological therapy.\u00a0GE Port J Gastroenterol. 2018;25(6):322\u20136. Available from: https:\/\/karger.com\/pjg\/article\/25\/6\/322\/274885. Accessed 13 Feb 2018","DOI":"10.1159\/000486448"},{"key":"1920_CR29","doi-asserted-by":"publisher","unstructured":"Salda\u00f1a Due\u00f1as C, Rubio Iturria S. Immunodeficiencies and autoimmune diseases: common variable immunodeficiency and Crohn-like.\u00a0Rev Esp Enferm Dig.\u00a02015;108(8):520\u201323. https:\/\/doi.org\/10.17235\/reed.2015.3872\/2015","DOI":"10.17235\/reed.2015.3872\/2015"},{"key":"1920_CR30","doi-asserted-by":"crossref","unstructured":"Akazawa Y, Takeshima F, Yajima H, Imanishi D, Kanda T, Matsushima K et al. Infliximab therapy for Crohn\u2019s-like disease in common variable immunodeficiency complicated by massive intestinal hemorrhage: a case report.\u00a0BMC Res Notes. 2014;7:382. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24952714\/. Accessed 22 June 2014","DOI":"10.1186\/1756-0500-7-382"},{"issue":"2","key":"1920_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1365-2249.2007.03481.x","volume":"150","author":"I Chua","year":"2007","unstructured":"Chua I, Standish R, Lear S, Harbord M, Eren E, Raeiszadeh M, et al. Anti-tumour necrosis factor-\u03b1 therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Experimental Immunol. 2007;150(2):306\u201311.","journal-title":"Clin Experimental Immunol"},{"key":"1920_CR32","doi-asserted-by":"crossref","unstructured":"Alventosa Mateu C, Ruiz S\u00e1nchez L, Amor\u00f3s Garc\u00eda C. Ulcerative colitis in a patient with common variable immunodeficiency: does the treatment differ from the routine?\u00a0Rev Esp Enferm Dig. 2016;108(4):235\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26912253\/","DOI":"10.17235\/reed.2016.4115\/2015"},{"key":"1920_CR33","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Mor\u00f3n JM, Pallar\u00e9s-Manrique H, Mart\u00edn-Su\u00e1rez IJ, Ben\u00edtez-Rodr\u00edguez B, Ramos-Lora M. Crohn\u2019s-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab.\u00a0Rev Esp Enferm Dig. 2013;105(5):299\u2013302. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23971663\/v. Accessed May-June 2013","DOI":"10.4321\/S1130-01082013000500010"},{"key":"1920_CR34","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2147\/JAA.S418996","volume":"16","author":"F Deng","year":"2023","unstructured":"Deng F, Wang H, Wang X. Chronic diarrhea with villous blunting of the small intestine under capsule endoscopy in common variable immunodeficiency and X-linked agammaglobulinemia: a case series. J Asthma Allergy. 2023;997\u20131006. https:\/\/doi.org\/10.2147\/JAA.S418996.","journal-title":"J Asthma Allergy"},{"issue":"9","key":"1920_CR35","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/ecco-jcc\/jjx024","volume":"11","author":"F Mu\u00f1oz","year":"2017","unstructured":"JG, Mu\u00f1oz F, Hernando M. Successful treatment of common variable Immunodeficiency-associated inflammatory bowel disease with ustekinumab. J Crohn\u2019s Colitis. 2017;11(9):1154\u20135.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"1","key":"1920_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-024-09559-5","volume":"73","author":"F Marley","year":"2024","unstructured":"Marley F, Lockett M, Gompels M, Grammatikos A. A patient with CVID-enteropathy successfully treated with ustekinumab. Immunol Res. 2024;73(1): 19. https:\/\/doi.org\/10.1007\/s12026-024-09559-5.","journal-title":"Immunol Res"},{"key":"1920_CR37","doi-asserted-by":"crossref","unstructured":"Johnson D, Lee G, Weber F. Vedolizumab therapy in refractory enteropathy associated with CVID.\u00a0ACG Case Rep J. 2022;9(1):e00721. Available from: https:\/\/journals.lww.com\/acgcr\/fulltext\/2022\/01000\/vedolizumab_therapy_in_refractory_enteropathy.3.aspx. Accessed 28 Dec 2021","DOI":"10.14309\/crj.0000000000000721"},{"issue":"3","key":"1920_CR38","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1053\/j.gastro.2021.12.225","volume":"162","author":"S Patel","year":"2022","unstructured":"Patel S, Wilhoit C, Williams K, Forster E. Vedolizumab as treatment for common variable immune deficiency (CVID): a case series and brief review of the literature. Gastroenterology. 2022;162(3):S111. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.225.","journal-title":"Gastroenterology"},{"key":"1920_CR39","doi-asserted-by":"publisher","unstructured":"Sifers T, Hirten R, Mehandru S, Ko HM, Colombel J-F, Cunningham-Rundles C. Vedolizumab therapy in common variable immune deficiency associated enteropathy: a case series. Clin Immunol. 2020;212:108362. https:\/\/doi.org\/10.1016\/j.clim.2020.108362.","DOI":"10.1016\/j.clim.2020.108362"},{"key":"1920_CR40","doi-asserted-by":"publisher","unstructured":"Akhtar HJ, Markandey B, Ma C, Ramsewak D, Walsh JC, Jairath V. Vedolizumab induced clinicndoscopic, and histological improvement in common variable immunodeficiency disease-associated intestinal enteropathy. Inflamm Bowel Dis [Internet]. 2020;26(4):e22\u20133. Available from: https:\/\/doi.org\/10.1093\/ibd\/izaa012. Accessed 31 Jan 2020","DOI":"10.1093\/ibd\/izaa012"},{"key":"1920_CR41","doi-asserted-by":"crossref","unstructured":"Boland BS, Riedl MA, Valasek MA, Crowe SE, Sandborn WJ. Vedolizumab in patients with common variable immune deficiency and gut inflammation. Am J Gastroenterol [Internet]. 2017 [cited 2025 Jan 13];112(10):1621. Available from: https:\/\/journals.lww.com\/ajg\/fulltext\/2017\/10000\/vedolizumab_in_patients_with_common_variable.34.aspx. Accessed Oct 2017","DOI":"10.1038\/ajg.2017.246"},{"key":"1920_CR42","doi-asserted-by":"crossref","unstructured":"Abdelmoumen A, van Montfrans J, van Wijk F, Leavis H. JAK Inhibition with Baricitinib for Severe CVID-Related Enteropathy: a Case Report.\u00a0J Clin Immunol.\u00a02023;43(8):1766\u20139. Available from: https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01569-6. Accessed 24 Aug 2023","DOI":"10.1007\/s10875-023-01569-6"},{"key":"1920_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clim.2018.09.008","volume":"197","author":"N Shulzhenko","year":"2018","unstructured":"Shulzhenko N, Dong X, Vyshenska Dariia, Greer RL, Gurung M, Vasquez-Perez S, et al. CVID enteropathy is characterized by exceeding low mucosal IgA levels and interferon-driven inflammation possibly related to the presence of a pathobiont. Clin Immunol. 2018;197:139\u201353.","journal-title":"Clin Immunol"},{"key":"1920_CR44","doi-asserted-by":"crossref","unstructured":"MarsdenJW, Lacl\u00e9 MM, Severs M, Leavis HL. Paucity of gastrointestinal plasma cells in common variable immunodeficiency.\u00a0Curr Opin Allergy Clin Immunol.\u00a02024;24(6):464\u201371. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11537466\/. Accessed Dec 2024","DOI":"10.1097\/ACI.0000000000001040"},{"issue":"6","key":"1920_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/ACI.0000000000000581","volume":"19","author":"IA Roos-Marijn Berbers, Franken","year":"2019","unstructured":"Roos-Marijn Berbers, Franken IA, Leavis HL. Immunoglobulin A and microbiota in primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol. 2019;19(6):563\u201370.","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01920-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-025-01920-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01920-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:46:07Z","timestamp":1777304767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-025-01920-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1920"],"URL":"https:\/\/doi.org\/10.1007\/s10875-025-01920-z","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HL attended advisory boards for Takeda, Sobi and Novartis, received honoraria for presenting at or moderation ofsymposia from Octopharma, Takeda, Novartis and Peerview, received research grants from Takeda, Novartis andSobi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"HL attended advisory boards for Takeda, Sobi and Novartis, received honoraria for presenting at or moderation of symposia from Octopharma, Takeda, Novartis and Peerview, received research grants from Takeda, Novartis and Sobi.N. Juliana declares no conflicts of interest.M. Severs declares no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of Conflicts of Interest"}}],"article-number":"129"}}